The largest genomic analysis ever conducted of small cell lung cancer tumors (SCLC) has identified genetic subtypes and provided insights into the mechanisms of this aggressive and deadly cancer.
A Vanderbilt study found that a molecular signature that predicts aggressive thyroid cancer could help guide treatment approaches for patients.
At the ripe age of 13, Jason Schwartz made a life-changing decision. Amid cancer treatment for Acute Lymphoblastic Leukemia (ALL), Schwartz was handed an incredible gift that would fuel his life’s work.
Research team refines method for diagnosis of indeterminant lung nodules using artificial intelligence and advanced learning.
Immunotherapy in combination with chemotherapy has become an important therapeutic treatment option in some patients with metastatic breast cancer. Which patients will benefit the most, however, remains unclear; current biomarkers such as PD-L1 that are used to predict response are mediocre at best.
Nicole Kidman and Keith Urban have made a generous financial gift to Vanderbilt-Ingram Cancer Center in support of clinical trials for new and better therapies for breast cancer.
Vanderbilt research shows that a liquid biopsy-based multicancer early detection (MCED) test could detect 12 types of cancers, including low DNA-shedding cancers and early-stage cancers.
The expected course of a patient's cancer prognosis has traditionally been judged by its type, stage and microscopic aggressiveness, but patients with the same presentation can still have widely divergent outcomes. Researchers from Vanderbilt-Ingram Cancer Center have discovered that differences in tumor mutation burden are a major reason for this divergence.
A broad bioinformatics approach revealed that Hedgehog signaling is upregulated in dedifferentiated liposarcoma, suggesting this pathway may be an early indicator of poor prognosis and a potential therapeutic target.
